

Validation and refinement of the Disease Risk Index for transplantation

Blood

123, 3664-3671

DOI: [10.1182/blood-2014-01-552984](https://doi.org/10.1182/blood-2014-01-552984)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions. Hematology American Society of Hematology Education Program, 2014, 2014, 570-575.	0.9	23
2	Getting fit for allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2014, 49, 1249-1250.	1.3	1
3	Genetic Stratification in Myeloid Diseases: From Risk Assessment to Clinical Decision Support Tool. Rambam Maimonides Medical Journal, 2014, 5, e0025.	0.4	1
4	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1758-1766.	2.0	52
5	Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 1516-1521.	2.0	50
6	Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031.	0.6	259
7	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	0.6	565
8	Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica, 2015, 100, 269-274.	1.7	28
9	<sc>ABCG</sc>2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. American Journal of Hematology, 2015, 90, 784-789.	2.0	16
10	HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Journal of Hematopoietic Cell Transplantation, 2015, 4, 9-22.	0.1	0
11	Reduced-intensity conditioned allogeneic SCT in adults with AML. Bone Marrow Transplantation, 2015, 50, 759-769.	1.3	34
12	Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1770-1775.	2.0	61
13	Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 1299-1307.	2.0	136
14	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
15	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology, 2015, 33, 2392-2398.	0.8	52
16	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
17	Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors. Biology of Blood and Marrow Transplantation, 2015, 21, 1641-1645.	2.0	38
18	Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality. Bone Marrow Transplantation, 2015, 50, 100-105.	1.3	72

#	ARTICLE	IF	CITATIONS
19	HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1646-1652.	2.0	88
20	Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. <i>Journal of Clinical Oncology</i> , 2015, 33, 3152-3161.	0.8	215
21	Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1136-1152.	13.9	2,466
22	Recent developments in HLA-haploidentical transplantations. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 141-146.	0.7	5
23	Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 28-34.	1.2	2
24	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.	1.7	54
25	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <i>American Journal of Hematology</i> , 2016, 91, E284-92.	2.0	59
26	T Cell Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1861-1866.	2.0	12
27	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.	1.7	53
28	Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Haematologica</i> , 2016, 101, e465-e468.	1.7	54
29	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. <i>Haematologica</i> , 2016, 101, 764-772.	1.7	20
30	Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 125-133.	2.0	135
31	Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. <i>Bone Marrow Transplantation</i> , 2016, 51, 1307-1312.	1.3	31
32	Nonmyeloablative allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016, 101, 521-530.	1.7	46
33	Impact of early CMV reactivation in cord blood stem cell recipients in the current era. <i>Bone Marrow Transplantation</i> , 2016, 51, 1113-1120.	1.3	36
34	Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 949-954.	1.3	20
35	Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1403-1409.	2.0	41
36	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	0.6	246

#	ARTICLE	IF	CITATIONS
37	Larger number of invariant natural killer T cells in PBSC allografts correlates with improved GVHD-free and progression-free survival. <i>Blood</i> , 2016, 127, 1828-1835.	0.6	52
38	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	13.9	352
39	Haploidentical cord transplantation—The best of both worlds. <i>Seminars in Hematology</i> , 2016, 53, 257-266.	1.8	24
40	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1808-1815.	2.0	29
41	Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1816-1822.	2.0	25
42	Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2092-2099.	2.0	6
43	Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1599-1601.	1.3	39
44	Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2047-2055.	2.0	45
45	Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. <i>Blood</i> , 2016, 128, 1528-1531.	0.6	46
46	Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1283-1300.	1.3	65
47	Life after transplant: are we becoming high maintenance in AML?. <i>Bone Marrow Transplantation</i> , 2016, 51, 1423-1430.	1.3	12
48	Donor Immunization Against Human Leukocyte Class II Antigens is a Risk Factor for Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 292-299.	2.0	20
49	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
50	Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (>=60 years). <i>Bone Marrow Transplantation</i> , 2016, 51, 1441-1448.	1.3	37
51	Impact of pre-transplant diffusion lung capacity for nitric oxide (DLNO) and of DLNO/pre-transplant diffusion lung capacity for carbon monoxide (DLNO/DLCO) ratio on pulmonary outcomes in adults receiving allogeneic stem cell transplantation for hematological diseases. <i>Bone Marrow Transplantation</i> , 2016, 51, 589-592.	1.3	5
52	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016, 3, e87-e98.	2.2	67
53	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 80-85.	2.0	14
54	Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2016, 103, 453-460.	0.7	31

#	ARTICLE	IF	CITATIONS
55	Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. <i>Bone Marrow Transplantation</i> , 2016, 51, 955-960.	1.3	6
56	Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. <i>Seminars in Hematology</i> , 2016, 53, 90-97.	1.8	118
57	Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 568-572.	1.3	36
58	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 71-79.	2.0	11
59	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	13.9	436
60	Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ≥ 65 years with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2016, 51, 157-160.	1.3	3
61	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
62	Cord blood chimerism and relapse after haplo-cord transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 288-297.	0.6	17
63	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
64	MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase. <i>Bone Marrow Transplantation</i> , 2017, 52, 778-780.	1.3	1
65	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
66	Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 677-683.	2.0	12
67	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2017, 102, 948-957.	1.7	33
68	Untreated donor specific antibodies against HLA are associated with poor outcomes in peripheral blood haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 898-901.	1.3	13
69	Aspirin Is Associated with Improved Survival in Severely Thrombocytopenic Cancer Patients with Acute Myocardial Infarction. <i>Oncologist</i> , 2017, 22, 213-221.	1.9	23
70	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 44-50.	1.2	12
71	Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 840-844.	2.0	10
72	Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogeneic Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1208-1214.	2.0	35

#	ARTICLE	IF	CITATIONS
73	Pre-transplant ferritin, albumin and haemoglobin are predictive of survival outcome independent of disease risk index following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 870-877.	1.3	21
74	Cryopreserved CD34 + Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after Single-Unit Cord Blood Transplantation in Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1142-1150.	2.0	52
75	Ex Vivo Mesenchymal Precursor Cellâ€“Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1359-1366.	2.0	22
76	Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemiaâ€“Lessons Learned from the Prospective BRIDGE Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1491-1497.	2.0	12
79	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. <i>Transplantation</i> , 2017, 101, e34-e38.	0.5	14
80	Against the odds: haplo-cord grafts protect from GvHD and relapse. <i>Bone Marrow Transplantation</i> , 2017, 52, 1590-1591.	1.3	4
81	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1485-1490.	2.0	7
82	Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2017, 52, 1273-1279.	1.3	11
83	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
84	Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 79-84.	0.6	14
85	Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. <i>Bone Marrow Transplantation</i> , 2017, 52, 918-921.	1.3	32
86	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	1.7	31
87	Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 1138-1143.	1.3	20
88	Clinical impact of hyperglycemia on days 0â€“7 after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1156-1163.	1.3	6
89	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
90	Ex Vivo CD34+â€“Selected T Cellâ€“Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> . 2017. 23. 452-458.	2.0	35
91	Post-Transplant Cyclophosphamide and Tacrolimusâ€“Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 459-466.	2.0	50
92	Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia. <i>Bone Marrow Transplantation</i> , 2017, 52, 445-451.	1.3	6

#	ARTICLE	IF	CITATIONS
93	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <i>British Journal of Haematology</i> , 2017, 179, 790-801.	1.2	9
94	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2096-2101.	2.0	27
95	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	1.7	64
96	Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2192-2198.	2.0	21
97	Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1949-1954.	2.0	4
98	Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1839-1846.	2.0	36
99	A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2151-2158.	2.0	9
100	Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies. <i>Clinics in Chest Medicine</i> , 2017, 38, 575-593.	0.8	11
101	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1736-1743.	2.0	44
102	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	0.6	210
103	An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication. <i>Bone Marrow Transplantation</i> , 2017, 52, 363-371.	1.3	4
104	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
105	ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. <i>Blood Advances</i> , 2017, 1, 573-576.	2.5	27
106	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 699-707.	0.9	4
107	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. <i>Blood Advances</i> , 2017, 1, 1347-1357.	2.5	8
108	Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2017, 1, 2473-2482.	2.5	16
109	Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 1650-1659.	0.8	252
110	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-“Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009.	0.8	255

#	ARTICLE	IF	CITATIONS
111	Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India. <i>Journal of Global Oncology</i> , 2017, 3, 773-781.	0.5	15
112	From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. <i>Stem Cell Investigation</i> , 2017, 4, 39-39.	1.3	4
113	High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2018, 180, 840-853.	1.2	15
114	The putative anti-leukemic effects of anti-thymocyte globulins in patients with CD7-positive acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2018, 53, 1019-1029.	1.3	6
115	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	1.7	38
116	Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. <i>Bone Marrow Transplantation</i> , 2018, 53, 756-763.	1.3	35
117	Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 90-95.	0.6	2
118	Epidemiology and biology of relapse after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1379-1389.	1.3	85
119	Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1237-1242.	2.0	12
120	Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status. <i>International Journal of Hematology</i> , 2018, 107, 551-558.	0.7	2
121	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	1.3	12
122	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
123	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018, 131, 1248-1257.	0.6	16
125	Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. <i>Transplantation Proceedings</i> , 2018, 50, 241-245.	0.3	2
126	Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
127	Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations. <i>European Journal of Haematology</i> , 2018, 100, 395-402.	1.1	19
128	Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 779-788.	2.0	24
129	Beneficial impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation: focusing on difference between stem cell sources. <i>Bone Marrow Transplantation</i> , 2018, 53, 634-639.	1.3	11

#	ARTICLE	IF	CITATIONS
130	Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. <i>Bone Marrow Transplantation</i> , 2018, 53, 576-583.	1.3	14
131	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 964-972.	2.0	19
132	Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two?. , 2018, , 159-171.		0
133	Graft Source: Marrow or Peripheral Blood with Posttransplant Cyclophosphamideâ€”What Matters?. , 2018, , 111-125.		0
134	Peripheral Blood Grafts for T Cellâ€”Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
135	Alemtuzumab vs antiâ€”thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. <i>European Journal of Haematology</i> , 2018, 101, 466-474.	1.1	5
136	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	0.6	140
137	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1733-1740.	2.0	23
138	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitorâ€”Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1463-1470.	2.0	31
139	Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 590-600.	0.6	3
140	Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 301-307.	2.0	35
141	Alterations of CCR5 and CCR7 expression on donor peripheral blood T cell subsets after mobilization with rhG-CSF correlate with acute graft-versus-host disease. <i>Clinical Immunology</i> , 2018, 191, 81-87.	1.4	3
142	Killer Cell Immunoglobulin-Like Receptorâ€”Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cellâ€”Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 549-554.	2.0	35
143	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2018, 103, 531-539.	1.7	25
144	Donor/Recipient Selection, Work-Up, and Safety. , 2018, , 141-154.		0
145	Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?. <i>Bone Marrow Transplantation</i> , 2018, 53, 3-10.	1.3	29
146	Establishing a Hematopoietic Stem Cell Transplantation Unit. , 2018, , .		2
147	T-cell-replete haploidentical transplantation in acute myeloid leukemia. <i>Experimental Hematology</i> , 2018, 58, 5-16.	0.2	7

#	ARTICLE	IF	CITATIONS
148	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
149	THE FUTURE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2018, 64, 675-680.	0.1	0
150	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	2.2	23
151	Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 105.	0.4	2
153	Haploidentical Stem Cell Transplantation. , 2018, , 291-305.		0
154	Sequential HLA mismatch haploidentical transplantation utilizing posttransplantation cyclophosphamide for GVHD prophylaxis in high-risk and relapsed/refractory AML/MDS. <i>American Journal of Hematology</i> , 2018, 93, 1524-1531.	2.0	17
155	Selecting the Right Lower Risk Patient For Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S25-S27.	0.2	0
156	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <i>Blood Advances</i> , 2018, 2, 909-922.	2.5	76
157	Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. <i>Blood Advances</i> , 2018, 2, 2095-2103.	2.5	66
158	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018, 2, 299-307.	2.5	69
159	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , 2018, 2, 1180-1186.	2.5	35
160	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. <i>Blood Advances</i> , 2018, 2, 3590-3601.	2.5	16
161	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1203-1208.	2.0	1
162	Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1841-1847.	2.0	27
163	Validation of the Revised Pretransplant Assessment of Mortality Score in Patients with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1947-1951.	2.0	4
164	Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. <i>Bone Marrow Transplantation</i> , 2018, 53, 1498-1507.	1.3	9
165	Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2018, 101, 332-339.	1.1	11
166	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2047-2055.	2.0	18

#	ARTICLE	IF	CITATIONS
167	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , 2018, 32, 1787-1794.	3.3	36
168	What the internist should know about stem cell transplant in the elderly patient. <i>European Journal of Internal Medicine</i> , 2018, 58, 43-47.	1.0	0
169	Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults. , 2018, , 1596-1607.		0
170	Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 179.	1.7	22
171	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7
172	Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2517-2522.	2.0	13
173	Bridging Strategies to Allogeneic Transplant for Older AML Patients. <i>Cancers</i> , 2018, 10, 232.	1.7	6
174	Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2018, 108, 282-289.	0.7	3
176	Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation for Adults: Risk Factors and Clinical Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1873-1880.	2.0	13
178	Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. <i>American Journal of Hematology</i> , 2018, 93, 1014-1019.	2.0	3
180	Allogeneic Stem Cell Transplantation for MDS. <i>Hematologic Malignancies</i> , 2018, , 141-157.	0.2	0
181	Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 629-638.	0.6	4
182	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 137-144.	2.0	36
183	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
184	Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 ⁺ cells. <i>British Journal of Haematology</i> , 2019, 185, 570-573.	1.2	17
185	Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 432-441.	1.3	69
186	Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 99-122.	1.3	24
187	Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460.	2.0	27

#	ARTICLE	IF	CITATIONS
188	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. <i>EClinicalMedicine</i> , 2019, 15, 33-41.	3.2	8
189	Early fluid overload predicts higher non-relapse and overall mortality in adults after single-unit cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 2096-2101.	1.3	8
190	Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. <i>Blood</i> , 2019, 134, 924-934.	0.6	199
191	Clinical outcomes in allogeneic haematopoietic stem cell transplantation: A comparison between young and elderly patients. Observational study. <i>European Journal of Cancer Care</i> , 2019, 28, e13122.	0.7	2
192	Impact of a Nutritional Risk Index on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2287-2296.	2.0	15
193	High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts. <i>Cytotherapy</i> , 2019, 21, 886-894.	0.3	2
194	Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. <i>Cancer Medicine</i> , 2019, 8, 5058-5067.	1.3	26
195	T-Cell Replete Haploidentical Transplantation. , 2019, , 99-123.		1
196	Azacitidine as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e58.	0.6	2
197	Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2211-2216.	2.0	13
198	Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease. <i>Leukemia Research</i> , 2019, 83, 106173.	0.4	8
199	Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2172-2180.	2.0	3
200	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers. <i>JAMA Oncology</i> , 2019, 5, 1739.	3.4	76
201	The Presence of a CMV Immunodominant Allele in the Recipient Is Associated With Increased Survival in CMV Positive Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Oncology</i> , 2019, 9, 888.	1.3	9
202	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , the, 2019, 6, e573-e584.	2.2	140
203	Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning—a matched pair analysis. <i>Annals of Hematology</i> , 2019, 98, 753-762.	0.8	8
204	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 103, 510-518.	1.1	19
205	A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-matched haploidentical donors. <i>Transplant International</i> , 2019, 32, 1322-1332.	0.8	24

#	ARTICLE	IF	CITATIONS
206	Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 1997.	2.2	43
207	Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2501-2506.	2.0	10
208	Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2019, 10, 2319.	2.2	25
209	Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. <i>Bone Marrow Transplantation</i> , 2019, 54, 1434-1442.	1.3	5
210	Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS. <i>International Journal of Hematology</i> , 2019, 110, 347-354.	0.7	3
211	Association of Outcomes and Socioeconomic Status in Mexican Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2098-2102.	2.0	2
212	T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. <i>Nature Medicine</i> , 2019, 25, 1064-1072.	15.2	226
213	Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1621-1628.	2.0	8
214	Topoisomerase II inhibitors in AML: past, present, and future. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1637-1644.	0.9	25
215	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
216	Red blood cell transfusion burden by day 30 predicts mortality in adults after single-unit cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1836-1846.	1.3	5
217	Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2019, 54, 1686-1693.	1.3	3
218	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1456-1464.	2.0	18
219	Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1730-1737.	1.3	19
220	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1526-1535.	2.0	15
221	Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 105-109.	0.6	5
222	Donor-Specific Anti-HLA Antibodies in Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: Risk of Graft Failure, Poor Graft Function, and Impact on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1395-1406.	2.0	37
223	Impact of cyclosporine A concentration on acute graft-versus-host disease incidence after haploidentical hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2019, 103, 10-17.	1.1	17

#	ARTICLE	IF	CITATIONS
224	Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1465-1471.	2.0	2
225	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. <i>Frontiers of Medicine</i> , 2019, 13, 492-503.	1.5	5
226	Development of Pre-Engraftment Syndrome, but Not Acute Graft-versus-Host Disease, Reduces Relapse Rate of Acute Myelogenous Leukemia after Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1187-1196.	2.0	14
227	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. <i>Leukemia and Lymphoma</i> , 2019, 60, 1693-1696.	0.6	22
228	Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1614-1624.	1.3	10
229	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. <i>Journal of Immunology</i> , 2019, 202, 2141-2152.	0.4	32
231	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12
232	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019, 3, 2836-2844.	2.5	38
233	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. <i>Blood Advances</i> , 2019, 3, 230-236.	2.5	15
234	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	2.5	25
235	Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults. <i>Blood Advances</i> , 2019, 3, 12-20.	2.5	27
236	BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. <i>Blood Advances</i> , 2019, 3, 1750-1760.	2.5	6
237	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. <i>Blood Advances</i> , 2019, 3, 1858-1867.	2.5	25
238	Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation. <i>Blood Advances</i> , 2019, 3, 3351-3359.	2.5	25
239	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. <i>Blood Advances</i> , 2019, 3, 2454-2464.	2.5	12
240	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019, 3, 1881-1890.	2.5	73
241	Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. <i>Blood Advances</i> , 2019, 3, 2608-2616.	2.5	20
242	Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 3437-3443.	0.3	5

#	ARTICLE	IF	CITATIONS
243	Posttransplant maintenance therapy for acute leukemias. <i>Current Opinion in Hematology</i> , 2019, 26, 96-111.	1.2	2
244	The Proportional Relationship Between Pretransplant WT1 mRNA Levels and Risk of Mortality After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Not in Remission. <i>Transplantation</i> , 2019, 103, 2201-2210.	0.5	4
245	Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. <i>Blood Research</i> , 2019, 54, 290-295.	0.5	0
246	Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 707-716.	1.3	3
247	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292.	2.0	6
248	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 921-931.	2.0	21
249	Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1067-1076.	1.3	20
250	Allogeneic hematopoietic cell transplantation; the current renaissance. <i>Blood Reviews</i> , 2019, 34, 34-44.	2.8	67
251	Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. <i>International Journal of Hematology</i> , 2019, 109, 197-205.	0.7	10
252	Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients. <i>JAMA Oncology</i> , 2019, 5, 229.	3.4	33
253	Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 720-727.	2.0	47
255	Psychosocial Assessment of Candidates for Transplantation scale (PACT) and survival after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1013-1021.	1.3	18
256	CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 673-682.	2.0	21
257	Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.	2.0	7
258	Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. <i>Expert Review of Hematology</i> , 2019, 12, 99-106.	1.0	5
259	The Prognostic Impact of Pretransplantation Inflammatory and Nutritional Status in Adult Patients after Myeloablative Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 981-988.	2.0	13
260	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 861-867.	2.0	36
261	Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults. <i>International Journal of Hematology</i> , 2019, 109, 115-124.	0.7	4

#	ARTICLE	IF	CITATIONS
262	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 515-521.	2.0	24
263	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. <i>Bone Marrow Transplantation</i> , 2019, 54, 867-876.	1.3	8
264	The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 606-612.	2.0	10
265	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing <i>Clostridium difficile</i> Infection in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 2003-2009.	2.9	54
266	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 839-848.	1.3	24
267	Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results. <i>Seminars in Hematology</i> , 2019, 56, 183-189.	1.8	8
268	The use of comprehensive geriatric assessment in older patients before allogeneic hematopoietic stem cell transplantation: A cross-sectional study. <i>Journal of Geriatric Oncology</i> , 2020, 11, 100-106.	0.5	19
269	Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 349-355.	1.3	18
270	Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 139-144.	2.0	4
271	Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. <i>JAMA Oncology</i> , 2020, 6, e192974.	3.4	15
272	Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). <i>Science China Life Sciences</i> , 2020, 63, 571-581.	2.3	26
273	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 197-203.	2.0	16
274	Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 157-164.	1.3	39
275	Pretransplant body mass index on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1175-1177.	1.3	4
276	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	3.3	36
277	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> . 2020. 26. 123-131.	2.0	9
278	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 669-672.	1.3	13
279	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 392-400.	2.0	23

#	ARTICLE	IF	CITATIONS
280	Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2020, 111, 120-130.	0.7	8
281	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
282	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
283	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.6	7
284	Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 316-322.	2.0	4
285	Tolerability and Efficacy of Treatment With Azacytidine as Prophylactic or Preemptive Therapy for Myeloid Neoplasms After Allogeneic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 377-382.	0.2	10
286	Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 367-372.	2.0	2
287	Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 758-763.	2.0	14
288	Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. <i>Annals of Hematology</i> , 2020, 99, 167-179.	0.8	12
289	Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	2.0	39
290	Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 745-757.	2.0	10
291	Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible. <i>Frontiers in Oncology</i> , 2020, 10, 1746.	1.3	2
292	Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2075-2081.	2.0	17
293	The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4812-4821.	2.5	12
294	A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e305-e308.	2.0	6
295	High-dose post-transplant cyclophosphamide impairs T _H 1 cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft. <i>Clinical and Translational Immunology</i> , 2020, 9, e1171.	1.7	9
296	Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. <i>Leukemia Research</i> , 2020, 96, 106419.	0.4	11
297	Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2839-2849.	0.6	19

#	ARTICLE	IF	CITATIONS
298	Preemptive interferon- β treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. <i>Scientific Reports</i> , 2020, 10, 20148.	1.6	7
299	Comparison of continuous versus intermittent infusion cyclosporine and impact on transplant related outcomes in allogeneic transplant recipients. <i>Journal of Oncology Pharmacy Practice</i> , 2020, , 107815522097060.	0.5	0
300	Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients. <i>Annals of Internal Medicine</i> , 2020, 172, 306.	2.0	45
301	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. <i>Journal of Immunology</i> , 2020, 205, 1441-1448.	0.4	9
302	Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 3474-3485.	2.5	13
303	Feasibility of thiotepea addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	0.6	1
304	Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy. <i>International Journal of Hematology</i> , 2020, 112, 697-706.	0.7	4
305	Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1655-1662.	2.0	8
306	Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation. <i>Blood Advances</i> , 2020, 4, 3829-3839.	2.5	10
307	Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience. <i>Cytotherapy</i> , 2020, 22, 445-449.	0.3	8
308	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	2.5	52
309	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	2.5	47
310	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. <i>Blood Advances</i> , 2020, 4, 3822-3828.	2.5	5
311	Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin. <i>Cell Transplantation</i> , 2020, 29, 096368972097656.	1.2	6
312	High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.	2.5	29
313	New-onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide. <i>EJHaem</i> , 2020, 1, 576-580.	0.4	2
314	A Systematic Review of Machine Learning Techniques in Hematopoietic Stem Cell Transplantation (HSCT). <i>Sensors</i> , 2020, 20, 6100.	2.1	24
315	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2020, 99, 1341-1350.	0.8	7

#	ARTICLE	IF	CITATIONS
316	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
317	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	1.3	24
318	Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2224-2233.	1.3	23
319	The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant – a retrospective study. <i>Transplant International</i> , 2020, 33, 1089-1098.	0.8	1
320	Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1068.	2.2	14
321	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703.	2.0	6
322	T Cell Clonal Dynamics Determined by High-Resolution TCR- β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1567-1574.	2.0	11
323	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020, 104, 1070-1080.	0.5	9
324	Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation. <i>International Journal of Hematology</i> , 2020, 111, 858-868.	0.7	20
325	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1298-1302.	2.0	14
326	Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020, 55, 1399-1409.	1.3	9
327	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1670-1678.	2.0	17
328	Predominant low Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) score in a Mexican referral center: a selection bias caused by limited-resources?. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 43, 249-255.	0.1	0
329	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
330	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1868-1875.	2.0	8
331	Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. <i>Clinical Transplantation</i> , 2020, 34, e14018.	0.8	10
332	Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. <i>Hematological Oncology</i> , 2020, 38, 597-603.	0.8	14
333	Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. <i>Bone Marrow Transplantation</i> , 2020, 55, 1161-1168.	1.3	11

#	ARTICLE	IF	CITATIONS
334	Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 2404-2410.	3.2	9
335	Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 1379-1387.	1.3	24
336	Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation. <i>Annals of Hematology</i> , 2020, 99, 591-598.	0.8	4
337	ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. <i>Leukemia</i> , 2020, 34, 1907-1923.	3.3	20
338	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <i>Cytotherapy</i> , 2020, 22, 158-165.	0.3	10
339	Infections after Allogeneic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1179-1188.	2.0	49
340	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	3.3	16
341	Incidence, Risk Factors, and Outcomes of Primary Prolonged Isolated Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1452-1458.	2.0	10
342	Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1312-1317.	2.0	49
343	The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1833-1841.	0.6	9
344	External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails. <i>Blood</i> , 2020, 135, 1386-1395.	0.6	36
345	Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 408-419.	2.5	38
346	The Changing Landscape of Treatment in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 343-354.	1.8	9
347	Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. <i>Blood Research</i> , 2020, 55, 27-34.	0.5	2
348	Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 129-136.	1.3	12
349	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	1.3	9
350	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	0.7	2
351	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta Oncologica</i> , 2021, 60, 466-474.	0.8	4

#	ARTICLE	IF	CITATIONS
352	Evaluation of Disease Risk Comorbidity Index after Allogeneic Stem Cell Transplantation in a Cohort with Patients Undergoing Transplantation with In Vitro Partially T Cell Depleted Grafts. Transplantation and Cellular Therapy, 2021, 27, 67.e1-67.e7.	0.6	1
353	Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Annals of Hematology, 2021, 100, 541-553.	0.8	25
354	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 2021, 56, 334-346.	1.3	9
355	CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies. Bone Marrow Transplantation, 2021, 56, 185-194.	1.3	7
356	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplantation and Cellular Therapy, 2021, 27, 68.e1-68.e9.	0.6	15
357	Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients. Transplantation and Cellular Therapy, 2021, 27, 75.e1-75.e10.	0.6	4
358	Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia. Bone Marrow Transplantation, 2021, 56, 586-595.	1.3	15
359	Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. Bone Marrow Transplantation, 2021, 56, 635-645.	1.3	9
360	Ex vivo Tâ€cell depletion vs postâ€transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graftâ€vsâ€host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	1.1	2
361	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. Blood, 2021, 137, 983-993.	0.6	20
362	High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease. Annals of Hematology, 2021, 100, 1321-1328.	0.8	10
363	Weightâ€based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. European Journal of Haematology, 2021, 106, 205-212.	1.1	1
364	Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects. Transplantation and Cellular Therapy, 2021, 27, 144-151.	0.6	12
365	Guidelines for Adult Patient Selection and Conditioning Regimens in Cord Blood Transplant Recipients with Hematologic Malignancies and Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 286-291.	0.6	10
366	Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study. Bone Marrow Transplantation, 2021, 56, 1099-1105.	1.3	10
367	Combining the disease risk index and hematopoietic cell transplant coâ€morbidity index provides a comprehensive prognostic model for CD34 ⁺ â€selected allogeneic transplantation. Advances in Cell and Gene Therapy, 2021, 4, .	0.6	0
368	Fresh <i>vs.</i> frozen allogeneic peripheral blood stem cell grafts: A successful timely option. American Journal of Hematology, 2021, 96, 179-187.	2.0	23
369	An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation. Transplantation and Cellular Therapy, 2021, 27, 327.e1-327.e11.	0.6	4

#	ARTICLE	IF	CITATIONS
370	Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 517-527.	0.8	7
371	Risk of relapse in patients receiving azithromycin after allogeneic HSCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 960-962.	1.3	3
372	Inpatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy. <i>International Journal of Hematology</i> , 2021, 113, 63-72.	0.7	2
373	Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. <i>Hematology</i> , 2021, 26, 186-198.	0.7	3
374	Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 584520.	2.2	11
375	Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning. <i>Leukemia and Lymphoma</i> , 2021, 62, 1619-1628.	0.6	5
376	Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level. <i>Annals of Hematology</i> , 2021, 100, 789-798.	0.8	5
377	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-797.	1.3	5
378	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. <i>Transplant Infectious Disease</i> , 2021, 23, e13548.	0.7	7
379	Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes. <i>Clinical Hematology International</i> , 2021, 3, 34.	0.7	5
380	Harmonization, biomarkers, disease risk index. <i>Blood</i> , 2021, 137, 874-875.	0.6	0
381	Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 373-385.	0.8	11
382	Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. <i>Medicine (United States)</i> , 2021, 100, e24725.	0.4	1
383	Favorable Outcomes after Single Cord Blood Transplantation for Patients with High-Risk Hematologic Diseases: A Single-Institute Retrospective Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 495.e1-495.e9.	0.6	7
384	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 840-850.	0.7	7
385	Disease Risk Comorbidity Index for Patients Receiving Haploidentical Allogeneic Hematopoietic Transplantation. <i>Engineering</i> , 2021, 7, 162-169.	3.2	11
386	Increased blood transfusion after outpatient autologous transplantation with reduced intensity conditioning for hematological malignancies predicts worse outcomes. <i>Clinical Transplantation</i> , 2021, 35, e14247.	0.8	0
387	Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2021, 100, 1295-1301.	0.8	2

#	ARTICLE	IF	CITATIONS
388	Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. <i>Bone Marrow Transplantation</i> , 2021, 56, 1603-1613.	1.3	11
389	Pretransplant plasma brain natriuretic peptide and N-terminal probrain natriuretic peptide are more useful prognostic markers of overall survival after allogeneic hematopoietic cell transplantation than echocardiography. <i>Bone Marrow Transplantation</i> , 2021, 56, 1467-1470.	1.3	1
390	Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 614488.	2.2	6
391	Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1584-1592.	1.3	0
392	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <i>Blood Advances</i> , 2021, 5, 1352-1359.	2.5	14
393	Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend when and for whom in 2021?. <i>Haematologica</i> , 2021, 106, 1794-1804.	1.7	36
394	Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 1360-1368.	2.5	39
395	Risk stratification systems for allogeneic haematopoietic stem-cell transplantation. <i>Lancet Haematology</i> , 2021, 8, e166-e167.	2.2	0
396	ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 256.e1-256.e7.	0.6	12
397	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
398	Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1199-1208.	2.5	34
399	Pretransplant increasing rate of lactate dehydrogenase as a predictor of transplant outcomes for patients with myeloid hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 1732-1736.	1.3	1
400	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	0.4	4
401	Stem Cell Transplantation in Acute Myeloid Leukemia. , 0, , .		0
402	Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 1683-1690.	1.3	12
403	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , 2021, 8, e205-e215.	2.2	26
404	Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients. <i>International Journal of Hematology</i> , 2021, 114, 85-93.	0.7	3
405	Post-Transplant Cyclophosphamide and Tacrolimus/Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1173.	1.0	10

#	ARTICLE	IF	CITATIONS
406	Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1405-1414.	3.0	13
407	Sinusoidal Obstruction Syndrome in Critically Ill Patients in the Era of Defibrotide: A Retrospective Multicenter Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 338.e1-338.e7.	0.6	4
408	Early-Phase Peripheral Blood Eosinophilia Predicts Lower Overall and Non-Relapse Mortality After Single-Unit Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 336.e1-336.e9.	0.6	1
409	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
410	Risk Factor and Long-Term Outcome Analyses for Acute Limbic Encephalitis and Calcineurin Inhibitor-Induced Encephalopathy in Adults following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 437.e1-437.e9.	0.6	2
411	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. <i>Bone Marrow Transplantation</i> , 2021, 56, 2355-2366.	1.3	23
412	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 428.e1-428.e9.	0.6	11
413	Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience From the Madrid Group of Hematopoietic Transplant. <i>Frontiers in Immunology</i> , 2021, 12, 674658.	2.2	10
414	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	2.8	4
415	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2231-2240.	1.3	6
416	Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2021, 56, 2432-2444.	1.3	33
417	Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. <i>Cancers</i> , 2021, 13, 2699.	1.7	11
418	A high transfusion burden following an ambulatory-allogeneic hematopoietic cell transplantation using reduced-intensity conditioning is associated with adverse outcomes. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102537.	0.6	0
419	The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft. <i>Bone Marrow Transplantation</i> , 2021, 56, 2284-2286.	1.3	0
420	Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 380-388.	0.6	4
421	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2690-2696.	1.3	6
422	Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. <i>Turkish Journal of Haematology</i> , 2021, 38, 138-144.	0.2	0
423	Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1437-1442.	0.7	0

#	ARTICLE	IF	CITATIONS
424	Biomarker profile predicts clinical efficacy of extracorporeal photopheresis in steroid-resistant acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant. <i>Journal of Clinical Apheresis</i> , 2021, 36, 697-710.	0.7	8
425	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial. <i>Science Bulletin</i> , 2021, 66, 2498-2505.	4.3	44
426	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <i>European Journal of Haematology</i> , 2021, 107, 354-363.	1.1	1
427	Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e559-e568.	0.2	3
428	Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. <i>Blood Advances</i> , 2021, 5, 2650-2659.	2.5	29
429	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.	0.6	26
430	Momentum of neutrophil recovery using an exponential growth model predicts the prognosis of single cord blood transplantation. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1465-1471.	0.7	0
431	Hematopoietic Cell Transplant-Composite Risk (HCT-CR): A Novel Predictor of Prognosis in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation Proceedings</i> , 2021, 53, 2013-2020.	0.3	0
432	Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal. <i>Cytotherapy</i> , 2021, 23, 635-640.	0.3	14
433	ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. <i>Transplantation Direct</i> , 2021, 7, e724.	0.8	2
434	Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 614.e1-614.e8.	0.6	2
435	FLAMSA-Busulfan-Melphalan as a Sequential Conditioning Regimen in HLA-Matched or Haploidentical Hematopoietic Stem Cell Transplantation for High-Risk Myeloid Diseases. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 915.e1-915.e8.	0.6	4
436	Risk Factors for and the Prognostic Impact of Pericardial Effusion after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 949.e1-949.e8.	0.6	1
437	Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients. <i>Frontiers in Oncology</i> , 2021, 11, 705568.	1.3	4
438	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	0.6	15
439	A randomized double-blind placebo-controlled trial of intravenous thiamine for prevention of delirium following allogeneic hematopoietic stem cell transplantation. <i>Journal of Psychosomatic Research</i> , 2021, 146, 110503.	1.2	6
440	A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). <i>Leukemia and Lymphoma</i> , 2021, 62, 3181-3191.	0.6	4
441	Treatment Approaches of Multiple Myeloma. , 0, , .		1

#	ARTICLE	IF	CITATIONS
442	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2021, 56, 2723-2731.	1.3	4
443	Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience. <i>Haematologica</i> , 2021, 106, 3017-3020.	1.7	2
444	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2763-2770.	1.3	25
445	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	0.6	6
446	Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 660.e1-660.e8.	0.6	5
447	Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2897-2903.	1.3	10
448	Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 912.e1-912.e6.	0.6	3
449	Kinetics of IgG subclasses and their effects on the incidence of infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Immunology</i> , 2021, 67, 101413.	0.6	1
450	Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. <i>American Journal of Hematology</i> , 2021, 96, 1429-1440.	2.0	1
451	Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an <sc>HLA</sc>-matched sibling donor. <i>American Journal of Hematology</i> , 2021, 96, 1441-1449.	2.0	7
452	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , 2021, 62, 3373-3383.	0.6	12
453	Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2021, 96, 1275-1286.	2.0	4
454	Comparison of 2 Different Doses of Antithymocyte Globulin in Conditioning Regimens for Haploidentical Hematopoietic Stem Cell Transplantation. <i>Experimental and Clinical Transplantation</i> , 2022, 20, 69-76.	0.2	0
455	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. <i>Medicina Clínica</i> , 2021, , .	0.3	1
456	Human Herpesvirus 6 DNAemia Is Associated With Worse Survival After Ex Vivo T-Cell-Depleted Hematopoietic Cell Transplant. <i>Journal of Infectious Diseases</i> , 2022, 225, 453-464.	1.9	2
457	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 669.e1-669.e8.	0.6	4
458	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	2.5	5
459	Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT. <i>Frontiers in Oncology</i> , 2021, 11, 732088.	1.3	2

#	ARTICLE	IF	CITATIONS
460	Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1261-1280.	0.7	3
461	Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 443-449.	0.6	0
462	Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 798.e1-798.e10.	0.6	13
464	Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. <i>Cancer Medicine</i> , 2021, 10, 7194-7202.	1.3	4
465	Outcomes of pediatric patients with therapy-related myeloid neoplasms. <i>Bone Marrow Transplantation</i> , 2021, 56, 2997-3007.	1.3	4
466	Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. <i>Annals of Hematology</i> , 2022, 101, 177-189.	0.8	4
467	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 784.e1-784.e7.	0.6	4
468	Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2021, 114, 664-673.	0.7	2
469	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	0.6	26
470	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.	0.6	17
471	Disruption of the oral microbiota is associated with a higher risk of relapse after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2021, 11, 17552.	1.6	16
472	Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 861.e1-861.e7.	0.6	0
473	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 875.e1-875.e9.	0.6	1
474	Allogeneic Transplant Overview and Matched Related Donor Transplant. <i>Organ and Tissue Transplantation</i> , 2021, , 187-221.	0.0	0
475	Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults. <i>International Journal of Hematology</i> , 2021, 113, 693-702.	0.7	3
476	Cardiopulmonary performance in allogeneic hematopoietic cell transplantation recipients—evaluation of pre-transplant risk assessments. <i>Bone Marrow Transplantation</i> , 2021, 56, 1325-1334.	1.3	1
477	± T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. <i>Blood Advances</i> , 2021, 5, 240-249.	2.5	21
478	The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact. <i>British Journal of Haematology</i> , 2021, 192, 467-473.	1.2	20

#	ARTICLE	IF	CITATIONS
479	Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 384, 11-19.	13.9	47
480	Evaluation and Counseling of Candidates. , 2019, , 77-86.		4
481	Toxicity of Conditioning Regimens in Haploidentical SCT. <i>Pancreatic Islet Biology</i> , 2017, , 43-56.	0.1	1
482	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
483	Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1597-1606.	2.0	7
484	Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 596-604.	1.3	28
485	Interactive Web Application for Plotting Personalized Prognosis Prediction Curves in Allogeneic Hematopoietic Cell Transplantation Using Machine Learning. <i>Transplantation</i> , 2021, 105, 1090-1096.	0.5	9
486	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. <i>BMJ Open</i> , 2020, 10, e040467.	0.8	4
487	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	0.6	164
488	Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0130026.	1.1	40
489	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	0.8	17
490	Cytokine release syndrome after haploidentical hematopoietic stem cell transplantation with antithymocyte globulin: risk factors analysis and poor impact on outcomes for non-remission patients. <i>Hematology</i> , 2021, 26, 809-817.	0.7	3
491	Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	0
492	Since everyone has a donor, why are some eligible patients still not transplanted?. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101321.	0.7	1
493	Psychosocial Pre-Transplant Screening With the Transplant Evaluation Rating Scale Contributes to Prediction of Survival After Hematopoietic Stem Cell Transplantation. <i>Frontiers in Psychiatry</i> , 2021, 12, 741438.	1.3	4
494	Anti- θ 1 thymocyte globulin and post- θ 1 transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , 2022, 108, 61-72.	1.1	9
495	Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. <i>Blood Advances</i> , 2021, 5, 5047-5056.	2.5	10
496	Advances in immune therapies in hematological malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 205-220.	2.7	5

#	ARTICLE	IF	CITATIONS
497	Poor survival and prediction of prolonged isolated thrombocytopenia post umbilical cord blood transplantation in patients with hematological malignancies. <i>Hematological Oncology</i> , 2022, 40, 83-92.	0.8	3
498	Single-Nucleotide Polymorphisms in MICA and MICB Genes Could Play a Role in the Outcome in AML Patients after HSCT. <i>Journal of Clinical Medicine</i> , 2021, 10, 4636.	1.0	2
499	Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4Â Gy TBI versus fludarabine/ busulfan plus 4Â Gy TBI. <i>International Journal of Hematology</i> , 2022, 115, 244-254.	0.7	0
500	Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 106-112.	1.3	0
501	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	1.3	8
502	Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. <i>Lancet Haematology</i> , the, 2021, 8, e853-e861.	2.2	18
503	Allogene Stammzelltransplantation bei Älteren komorbiden Patienten. , 2016, , 1-11.		0
504	Outcome of Haploidentical Stem Cell Transplantation in Patients with Lymphoma. <i>Pancreatic Islet Biology</i> , 2017, , 119-140.	0.1	0
505	Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. , 2018, , 1211-1245.		0
506	Allogene Stammzelltransplantation bei Älteren komorbiden Patienten. , 2018, , 113-123.		0
507	Signaling Landscape of AML: The Story So Far. , 2018, , 233-262.		0
508	Comparative Study of Mycophenolate Mofetil and Methotrexate in Graft-Versus-Host Disease Prophylaxis in Adult Recipients of Related and Unrelated Allo-HSCT. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2019, 12, 43-50.	0.1	0
509	HSCT in Elderly Patients. , 2019, , 499-503.		3
511	Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 635-643.	2.3	11
512	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	1.3	3
513	Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation. <i>Transfusion and Apheresis Science</i> , 2021, , 103301.	0.5	0
514	Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 183-190.	1.3	12
515	Impact of a prior history of cancer on prognosis after myeloablative single-unit cord blood transplantation. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 657-660.	0.6	0

#	ARTICLE	IF	CITATIONS
516	Allogeneic Transplant Overview and Matched Related Donor Transplant. Organ and Tissue Transplantation, 2020, , 1-34.	0.0	0
517	Characterization of myeloid neoplasms following allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2021, , .	2.0	2
518	Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation. British Journal of Haematology, 2022, 196, 735-742.	1.2	3
519	<p>Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes</p>. Cancer Management and Research, 2020, Volume 12, 12287-12300.	0.9	1
521	Antithymocyte globulin exposure in CD34+ T-cellâ€“depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	2.5	12
522	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. Blood Advances, 2022, 6, 574-584.	2.5	6
523	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 2022, 57, 243-251.	1.3	2
524	A novel Iowaâ€“Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction. Blood Cancer Journal, 2021, 11, 183.	2.8	0
525	Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. Transplantation and Cellular Therapy, 2021, 28, 88-88.	0.6	10
526	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8.	0.6	16
527	Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. Cytotherapy, 2022, 24, 413-420.	0.3	2
528	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	0.8	79
529	Effect of donor characteristics on T cellâ€“replete haploidentical stem cell transplantation over the last 10â€“years at a single institution. British Journal of Haematology, 2022, 196, 1225-1238.	1.2	7
531	Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. Frontiers in Cellular and Infection Microbiology, 2021, 11, 805514.	1.8	7
532	Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110680.	0.7	0
533	BMT for Myelodysplastic Syndrome: When and Where and How. Frontiers in Oncology, 2021, 11, 771614.	1.3	7
534	HLA 1â€“3 antigenâ€“mismatched related peripheral blood stem cells transplantation using lowâ€“dose antithymocyte globulin versus unrelated cord blood transplantation. American Journal of Hematology, 2022, 97, 311-321.	2.0	2
535	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	0.6	11

#	ARTICLE	IF	CITATIONS
536	Short-term methotrexate plus cyclosporine for graft-versus-host disease prophylaxis after single-unit cord blood transplantation following reduced-intensity conditioning. <i>Journal of Illusion</i> , 2022, 11, 64-71.	0.0	0
537	Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation. <i>Experimental Hematology</i> , 2022, 108, 36-45.	0.2	2
538	Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 204.e1-204.e10.	0.6	6
539	Prediction and recommendation by machine learning through repetitive internal validation for hepatic veno-occlusive disease/sinusoidal obstruction syndrome and early death after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	3
540	The impact of intestinal microbiota in antithymocyte globulinâ€based myeloablative allogeneic hematopoietic cell transplantation. <i>Cancer</i> , 2022, 128, 1402-1410.	2.0	5
541	Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors. <i>Cancers</i> , 2022, 14, 325.	1.7	16
542	Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies. <i>Transfusion and Apheresis Science</i> , 2022, , 103367.	0.5	3
543	Effectiveness of defibrotide in the prevention of hepatic venoocclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience. <i>Transfusion and Apheresis Science</i> , 2022, , 103369.	0.5	2
544	Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. <i>Blood Advances</i> , 2022, 6, 1895-1903.	2.5	5
545	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1686-1693.	0.6	2
546	Targeting an alternate Wilmsâ€™ tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	5.8	12
547	Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 829670.	2.2	2
548	Possible prognostic impact of WT1 mRNA expression at dayâ€30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group. <i>International Journal of Hematology</i> , 2022, 115, 515-524.	0.7	1
549	Age Adjusted Comorbidity Risk Index Does Not Predict Outcomes in an Autologous Hematopoietic Stem Cell Transplant Population. <i>Cell Transplantation</i> , 2022, 31, 096368972210803.	1.2	1
550	Radiation-free reduced-intensity hematopoietic stem cell transplantation with in vivo T-cell depletion from matched related and unrelated donors for Fanconi anemia: prognostic factor analysis. <i>Experimental Hematology</i> , 2022, 109, 27-34.	0.2	4
551	Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML. <i>Leukemia</i> , 2022, , .	3.3	7
552	Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	2
553	Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry. <i>Cancers</i> , 2022, 14, 1097.	1.7	4

#	ARTICLE	IF	CITATIONS
554	The Two-Step Allogeneic Stem Cell Transplantation Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 159.e1-159.e5.	0.6	2
555	Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
556	Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	3
557	Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	0
558	Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning-Based Model Development and Validation. <i>JMIR Medical Informatics</i> , 2022, 10, e32313.	1.3	3
559	Association of Leukocyte Adhesion and Rolling in Skin With Patient Outcomes After Hematopoietic Cell Transplantation Using Noninvasive Reflectance Confocal Videomicroscopy. <i>JAMA Dermatology</i> , 2022, , .	2.0	1
560	Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study. <i>Bone Marrow Transplantation</i> , 2022, 57, 843-845.	1.3	2
561	External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study. <i>HemaSphere</i> , 2022, 6, e704.	1.2	2
562	Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 169.e1-169.e9.	0.6	7
563	Benchmarking survival outcomes: A funnel plot for survival data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1171-1183.	0.7	5
565	Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning. <i>Blood Advances</i> , 2022, 6, 2618-2627.	2.5	12
566	Allogeneic haematopoietic stem cell transplantation—clinical outcomes: impact of leg muscle strength. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003256.	0.8	6
567	Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults. <i>Leukemia and Lymphoma</i> , 2021, , 1-11.	0.6	0
568	Single Cord Blood Transplantation Versus HLA-Haploidentical-related Donor Transplantation Using Posttransplant Cyclophosphamide in Patients With Hematological Malignancies. <i>Transplantation</i> , 2022, 106, 1279-1287.	0.5	4
569	Time-dependent analysis of adoptive immunotherapy following sequential FLAMSA-reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk myeloid neoplasia. <i>European Journal of Haematology</i> , 2022, 108, 244-263.	1.1	0
570	Anti-thymocyte Globulin and Post-transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen A and B mismatched donors. <i>European Journal of Haematology</i> , 2022, 108, 288-297.	1.1	4
571	Optimal time and threshold of absolute lymphocyte count recovery as a prognostic factor after single-unit cord blood transplantation in adults. <i>EJHaem</i> , 2022, 3, 191-198.	0.4	1
572	Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2022, 36, 1563-1574.	3.3	2

#	ARTICLE	IF	CITATIONS
573	Targeted Marrow Irradiation Intensification of Reduced Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	2
578	Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
581	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. <i>BMC Medicine</i> , 2022, 20, 140.	2.3	8
582	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. <i>Experimental Hematology and Oncology</i> , 2022, 11, 25.	2.0	19
583	Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	3
584	Pancreatic atrophy and recovery after allogeneic hematopoietic cell transplantation. <i>Journal of Gastroenterology</i> , 2022, 57, 571-580.	2.3	1
585	Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210908.	1.1	3
586	Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. <i>Blood Advances</i> , 2022, 6, 4763-4772.	2.5	4
587	Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1317-1323.	0.8	14
588	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1389-1398.	1.3	10
589	Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 451-457.	0.1	0
590	Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 744-753.	0.7	4
591	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	0.6	13
592	A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. <i>Blood Advances</i> , 0, , .	2.5	3
594	Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience. <i>Leukemia Research</i> , 2022, 120, 106918.	0.4	7
595	A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies. <i>Cell Transplantation</i> , 2022, 31, 096368972211120.	1.2	2
596	The mythological chimera and new era of relapse prediction post-transplant. <i>Blood Reviews</i> , 2023, 57, 100997.	2.8	3
597	N-Acetylcysteine as Prophylactic Therapy for Transplantation-Associated Thrombotic Microangiopathy: A Randomized, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 764.e1-764.e7.	0.6	3

#	ARTICLE	IF	CITATIONS
598	Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
599	Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2022, 57, 1671-1680.	1.3	2
600	Higher Cryopreserved CD34+ Cell Dose Is Associated with Decreased Hepatic Venous-Obstructive Disease/Sinusoidal Obstruction Syndrome after Single-Unit Cord Blood Transplantation in Adults Given Prophylactic Ursodeoxycholic Acid and Intravenous Heparin. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 779.e1-779.e9.	0.6	3
601	Time-dependent prediction of mortality and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation using machine learning. <i>American Journal of Hematology</i> , 2022, 97, 1309-1323.	2.0	5
602	Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1681-1688.	1.3	8
603	Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
604	Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2987-2991.	0.6	1
605	Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease. <i>Cytotherapy</i> , 2022, 24, 1225-1231.	0.3	1
606	Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study. <i>Leukemia Research</i> , 2022, 122, 106934.	0.4	0
607	Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. <i>Cancers</i> , 2022, 14, 4266.	1.7	0
609	Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies. <i>Annals of Transplantation</i> , 0, 27, .	0.5	1
610	Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1781-1787.	1.3	5
612	Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis. <i>American Journal of Hematology</i> , 2022, 97, 1568-1579.	2.0	3
613	Reduced dose post-transplant cyclophosphamide plus low dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial. <i>British Journal of Haematology</i> , 2023, 200, 210-221.	1.2	9
615	Conditioning Regimens in Allogeneic Hematopoietic Stem Cell Transplantation Do Not Fit All: Adjusting BuCy2 in Mexico to Improve Outcomes in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	0
616	Rituximab Toxicity after Preemptive or Therapeutic Administration for Post-Transplant Lymphoproliferative Disorder. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 43.e1-43.e8.	0.6	4
617	Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
618	Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study. <i>Annals of Medicine</i> , 2022, 54, 2616-2625.	1.5	2

#	ARTICLE	IF	CITATIONS
619	Low-dose total body irradiation promotes T-cells donor chimerism in reduced-intensity/non-myeloablative allogeneic stem cell transplant with post-transplant cyclophosphamide. <i>Leukemia Research</i> , 2022, 123, 106969.	0.4	1
620	Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
621	Significance of Omitting Day 11 Mini-Dose Methotrexate for GVHD Prophylaxis After Unrelated Bone Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 119.e1-119.e7.	0.6	1
622	EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2023, 58, 247-256.	1.3	5
623	Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation. <i>Blood Science</i> , 2023, 5, 51-59.	0.4	4
624	Novel risk assessment for the intensity of conditioning regimen in elderly patients. <i>Blood Advances</i> , 0, , .	2.5	0
625	Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis. <i>Annals of Hematology</i> , 0, , .	0.8	0
626	Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. <i>Annals of Medicine</i> , 2023, 55, 388-400.	1.5	5
627	Prognostic impact of the simple L-index and absolute lymphocyte count early after allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2023, , .	0.3	0
628	Pre-Transplant Total Lymphocyte Count Determines Anti-Thymocyte Globulin Exposure, Modifying Graft-versus-Host Disease Incidence and Post-Transplant Thymic Restoration: A Single-Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 730.	1.0	2
629	Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies. <i>Bone Marrow Transplantation</i> , 2023, 58, 386-392.	1.3	15
630	CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2023, 7, 2699-2708.	2.5	5
631	Multiplex proteomics using proximity extension assay for the identification of protein biomarkers predictive of acute graft-vs.-host disease in allogeneic hematopoietic cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1005-1014.	1.4	2
632	Clinical Benefit of Low-Dose Antithymocyte Globulin-Thymoglobulin as Graft-versus-Host Disease Prophylaxis in Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Identical Donors. <i>Transplantation and Cellular Therapy</i> , 2023, , .	0.6	0
633	Pre-transplant CRP/albumin ratio as a biomarker in patients receiving haploidentical allogeneic hematopoietic transplantation: Developing a novel DRCI-based nomogram. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
635	Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation. <i>International Journal of Hematology</i> , 0, , .	0.7	0
636	Determinants of refined GVHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. <i>Leukemia Research</i> , 2023, 127, 107052.	0.4	0
637	CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality. <i>Bone Marrow Transplantation</i> , 2023, 58, 639-646.	1.3	6

#	ARTICLE	IF	CITATIONS
638	Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT. <i>HemaSphere</i> , 2023, 7, e851.	1.2	1
639	Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies. <i>Blood Advances</i> , 2023, 7, 3297-3306.	2.5	1
640	Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2023, 58, 659-666.	1.3	2
641	Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement. <i>Lancet Respiratory Medicine</i> , 2023, 11, 477-492.	5.2	7
642	Bacterial Bloodstream Infections after Allogeneic Hematopoietic Stem Cell Transplantation: Etiology, Risk Factors and Outcome in a Single-Center Study. <i>Microorganisms</i> , 2023, 11, 742.	1.6	4
643	Adverse impact of a high $CD4/CD8$ ratio in the allograft may be overcome by methotrexate but not mycophenolate or post-transplant cyclophosphamide based graft versus host disease prophylaxis. <i>European Journal of Haematology</i> , 2023, 110, 715-724.	1.1	2
645	Characteristics of Distress and Support Group Participation in Caregivers of Older Allogeneic Hematopoietic Cell Transplantation Patients: A Single Institution Retrospective Review. <i>Journal of the Advanced Practitioner in Oncology</i> , 2023, 14, 127-137.	0.2	2
646	Incidence, Etiology, Risk Factors, and Outcomes of Bloodstream Infection after a Second Hematopoietic Stem Cell Transplantation. <i>Internal Medicine</i> , 2023, , .	0.3	0
647	Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes. <i>Blood Advances</i> , 2023, 7, 3644-3650.	2.5	2
648	A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	0